Antibodies News and Research

RSS

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

A new preprint research paper posted to the bioRxiv server reports the development of highly effective neutralizing nanobodies targeting the viral receptor-binding domain (RBD), thus disrupting its engagement with the host cell angiotensin-converting enzyme 2 (ACE2) receptor.

4 Feb 2021

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

A new preprint posted to the bioRxiv server demonstrates that similar mucins and mucin-like proteins cannot only suppress HIV-1 infectivity via blockage of viral attachment to the host cells but can block infection by multiple enveloped viruses.

4 Feb 2021

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Among these is the B.1.1.7 SARS-CoV-2 variant, with its characteristic N501Y mutation. A new preprint on the bioRxiv server reports the impact of this mutation on CD4 T cell responses, including antigen presentation on cells expressing Major Histocompatibility Complex (MHC) class II molecules.

4 Feb 2021

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

In the canton of Bern, only 14% of the adult population were infected with the coronavirus and developed antibodies against SARS-CoV-2.

4 Feb 2021

Emory MVA COVID-19 vaccine proven safe and effective in mice and monkeys

Researchers at Yerkes National Primate Research Center, Emory University, have developed a COVID-19 vaccine that has proven safe and effective in mice and monkeys.

4 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Novel biomarker may help identify which pancreatic cancer patients respond to CD40 agonists

Inflammation in the blood could serve as a new biomarker to help identify patients with advanced pancreatic cancer who won't respond to the immune-stimulating drugs known as CD40 agonists, suggests a new study from researchers in the Abramson Cancer Center of the University of Pennsylvania published in JCI Insight.

4 Feb 2021

Experimental vaccine diminishes fatal respiratory effects of synthetic opioids

As the opioid epidemic raged on with an even greater force during COVID-19, the Scripps Research laboratory of chemist Kim Janda, PhD, has been working on new therapeutic interventions that may be able to prevent the bulk of deaths from opioid overdose.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

Alzheimer's risk gene can increase COVID-19 susceptibility and severity

A City of Hope-led research team found that the same gene that increases the risk for Alzheimer's disease, ApoE4, can increase the susceptibility to and severity of COVID-19.

4 Feb 2021

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

A new study offers some reassuring findings, reporting the successful neutralization of the South African SARS-CoV-2 variant of concern (VOC) 501Y.V2 by two vaccines developed in China.

4 Feb 2021

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

A new study reports the underlying basis of increased transmissibility in the N501Y UK variant and provides reassuring data on the efficacy of the Pfizer vaccine and Eli Lilly monoclonal antibodies in neutralizing it.

4 Feb 2021

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

A new study server reports highly protective neutralizing monoclonal antibodies against the SARS-CoV-2.

4 Feb 2021

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

It is necessary to develop additional COVID-19 vaccines, as different vaccine approaches have their advantages and disadvantages and may work synergistically.

4 Feb 2021

Study shows how SARS-CoV-2 evades immune responses

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the University of Pittsburgh School of Medicine.

4 Feb 2021

SARS-CoV-2 has developed worrying new mutation in UK

Over the past few months, surging cases have been reported due to new fast-spreading variants. Now, Public Health England (PHE) investigates cases of COVID-19 with worrying new genetic changes. The E484K mutation, which could allow SARS-CoV-2 escape antibody protection, was seen in a small group of cases in some regions of the country.

4 Feb 2021

Antibodies News and Research

Alpaca nanobodies neutralize SARS-CoV-2 in vitro

SHREK proteins mediate broad spectrum antiviral host immunity, including against SARS-CoV-2

SARS-CoV-2 N501Y mutation adversely affects cellular immune response

Study: Only 14% of the Bernese population developed antibodies against SARS-CoV-2

Emory MVA COVID-19 vaccine proven safe and effective in mice and monkeys

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

Novel biomarker may help identify which pancreatic cancer patients respond to CD40 agonists

Experimental vaccine diminishes fatal respiratory effects of synthetic opioids

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Alzheimer's risk gene can increase COVID-19 susceptibility and severity

South African SARS-CoV-2 variant neutralized by two Chinese vaccines in case study

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Monoclonal antibodies against SARS-CoV-2 spike's N-terminal prove highly protective in vivo

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

Study shows how SARS-CoV-2 evades immune responses

SARS-CoV-2 has developed worrying new mutation in UK

Russia's Sputnik V COVID-19 shown to have 91.6 percent efficacy

Phase 1 clinical trial of novel HIV vaccine approach shows promising results

Experimental intranasal influenza vaccine produces durable immune response

Moffitt researchers reveal why some ovarian cancer patients evolve better than others

Immunology eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News